Master the Future of Healthcare Decision-Making in Asia
Applications are open from
1 Aug to 15 Dec 2026 (Aug 2027 Admissions)
Governments, healthcare systems, pharmaceutical companies, and medtech firms increasingly rely on Health Economics and Outcomes Research (HEOR) to make evidence-based decisions on pricing, reimbursement, and patient access. As healthcare costs rise across Asia, demand for professionals skilled in HEOR is rapidly growing globally.
This programme will equip professionals with the skills to evaluate the economic value and outcomes of health interventions and shape evidence-based healthcare policies and access strategies.
Asia’s Premier MSc in HEOR
As Singapore only specialised MScHEOR Masters programme, it is uniquely designed for Asian healthcare systems and the region’s evolving healthcare landscape. It equips professionals with the expertise to support evidence-based healthcare decision-making and offers excellent career prospects across government agencies, pharmaceutical and medtech companies, and public health organisations in Asia and beyond.
Career-Driven Curriculum with Real-World Impact
Develop industry-relevant expertise through capstone projects and applied learning in cost-effectiveness modelling, HTA, patient-centred outcomes research, and market access strategy. Designed to bridge theory and practice, the programme equips students with the analytical and decision-making skills to translate complex healthcare data into decision ready insights.
NUS: A Globally Recognised Institution
The National University of Singapore (NUS) is ranked first in Asia and eighth globally in the QS World University Rankings 2026. As a leading institution in public health and medicine, an NUS qualification provides graduates with opportunities in medical innovation, regulation, and policy evaluation.
Asia-Focused Learning with Regional Relevance
Teaching will reflect how evidence is used in Asian health systems, from assessment and priority-setting to coverage decisions. Strengthen your ability to communicate analyses that inform pricing and reimbursement outcomes across different policy and payer environments.
Teaching Team Blends Academic Excellence & Deep Practice Experience
NUS faculty bring academic depth and research leadership, complemented by industry and government experts who bring real-world experience and best practices. Together, they support learning that is immediately relevant to HTA methods, evidence generation, and decision-oriented communication.
Career Prospects
Public Sector
Health Technology Assessment agencies (e.g. ACE in Singapore), Ministries of Health, healthcare clusters (e.g. NUHS, NHG, Singhealth), statutory bodies (e.g. Health Promotion Board).
Private Sector
HEOR consultancies, pharmaceutical & MedTech companies, healthcare payers & insurers.
Academia
Universities, government research institutes, non-governmental think tanks.
Faculty Highlights
Associate Professor Alec Morton is the Programme Director of the MScHEOR programme at Saw Swee Hock School of Public Health. With over twenty years’ experience in decision modelling, HEOR and Health Technology Assessment, he bridges academic research, policy and practice across Asia, Europe and global public-health institutions.
He has collaborated with the WHO, Gavi and HTA agencies and ministries of health in Thailand, China and the UK. At NUS he leads the Centre for Population Health Risk and Systems Modelling (PHRISM) and has editorial roles at Health Care Management Science, Decision Analysis and the Journal of Multi-Criteria Decision Analysis.
Formerly Head of the Department of Management Science at the University of Strathclyde, Professor Morton’s research has received the INFORMS Decision Analysis Society Publication Award. His work has ranged across multiple areas of public health and health economics, including antimicrobial resistance, public mental health, and chronic disease surveillance and prevention.
Associate Professor Wee Hwee Lin is an internationally recognised expert in health technology assessment (HTA). As Director of the Centre for Health Intervention and Policy Evaluation Research (HIPER), she leads regional initiatives to strengthen HTA capacity, mentoring young researchers and advancing studies in economic evaluation of precision medicine, high-cost novel treatments as well as national cancer and chronic disease screening programmes.
Associate Professor Wee is widely recognized for her pioneering work using real-world data—from electronic medical records to patient preferences—to evaluate the cost-effectiveness of healthcare technologies. Her research has been used to inform policy decisions in Singapore and across ASEAN and her opinions are often sought by the local news media.
Beyond academia, she serves on key advisory committees, including Singapore’s National Advisory Committee on Cancer, the International Society for Pharmacoeconomics and Outcomes Research Health Sciences Policy Council (ISPOR HSPC), and the International Editorial Advisory Board for Journal of Patient Reported Outcomes (JPRO).
Assistant Professor Wang Yi is the Co-Director of the health technology assessment (HTA) unit of Centre for Health Intervention and Policy Evaluation Research (HIPER) and Co-Founder of the Medical Innovation Development and Assessment Support (MIDAS) unit.
He has extensive experience in health economics and outcomes research (HEOR) and HTA, with expertise spanning economic evaluations of digital health interventions, diagnostic tests, medical device, and screening programs across a range of diseases, including cancer, hypertension, diabetes, tuberculosis, and COVID-19.
Assistant Professor Wang also specialises in conjoint analysis, particularly discrete choice experiments, to understand population preferences in healthcare decision-making. He has led and contributed to HTA capacity-building efforts across Asia, including workshops and training programs in Singapore, Thailand, the Philippines, Brunei, Cambodia, and China.
Assistant Professor Cynthia Chen is a public health economist and Assistant Professor at the Saw Swee Hock School of Public Health. Her research focuses on the economics of ageing, healthcare financing, and health system innovation. She has led several large-scale health economic evaluations and simulation studies, including the Singapore Future Elderly Model (FEM-SG), which projects chronic disease burden, healthcare spending, and the long-term impact of preventive interventions.
Assistant Professor Chen works closely with government agencies in Singapore to provide economic evidence for policy decisions, including evaluations of national programmes such as the National Steps Challenge, and Age Well SG. Internationally, she serves on the Editorial Board of Nature Communications Medicine and as Academic Editor for PLOS Global Public Health. Her work spans health technology assessment (HTA), real-world evidence generation, and the use of econometric and modelling methods to inform health policy and resource allocation.
Assistant Professor Kiesha Prem is a public health researcher at the Saw Swee Hock School of Public Health. She specialises in infectious disease modelling, health economics, and health technology assessment (HTA). Her work has shaped global HPV vaccination policy through contributions to the Single-Dose HPV Vaccine Evaluation Consortium, where she led some of the modelling analyses that informed WHO’s 2022 recommendation for single-dose HPV schedules.
As Principal Investigator, she leads a regional network focusing on strategic health purchasing across Asia. She has also supported ministries of health on HTA and vaccine policy, including cost-effectiveness analyses of vaccination programmes. Assistant Professor Prem advises the Lao Food and Drug Department on economic evaluation. Beyond research, she has delivered HTA and modelling workshops across Southeast Asia, co-organised the Health Decision Science module at LSHTM, and coordinated courses at NUS. Her work bridges methodological rigour with real-world policy application, particularly in low- and middle-income country settings.
Assistant Professor Wenjia Chen is a health economist and HTA expert whose research bridges real-world data analytics with policy-relevant evidence generation. She leads cutting-edge research forecasting the economic burden of chronic diseases and multimorbidity using national health administrative data, with a special focus on health system planning under climate change.
Assistant Professor Chen also develops and evaluates AI-empowered clinical decision support (CDS) tools and precision medicine strategies, using global real-world evidence and economic modeling to optimise their clinical utility, cost-effectiveness, and national implementation strategy.
She recently developed a national reference case for precision medicine economic evaluation for Thailand’s HTA agency, designed for wider adoption across LMICs, and she has led the development of Risk of Exacerbation in Severe Asthma (RESA) prediction tool to be used online in over 300 specialist clinics worldwide. Assistant Professor Chen’s interdisciplinary expertise and translational focus position her as a leader in advancing the integration of HEOR and HTA into precision medicine and digital health innovation and policy.
